BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16357522)

  • 1. Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a Phase I trial.
    Ramos TC; Vinageras EN; Ferrer MC; Verdecia BG; Rupalé IL; Pérez LM; Marinello GG; Rodríguez RP; Dávila AL
    Cancer Biol Ther; 2006 Feb; 5(2):145-9. PubMed ID: 16357522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer.
    Neninger Vinageras E; de la Torre A; Osorio Rodríguez M; Catalá Ferrer M; Bravo I; Mendoza del Pino M; Abreu Abreu D; Acosta Brooks S; Rives R; del Castillo Carrillo C; González Dueñas M; Viada C; García Verdecia B; Crombet Ramos T; González Marinello G; Lage Dávila A
    J Clin Oncol; 2008 Mar; 26(9):1452-8. PubMed ID: 18349395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy.
    Rodríguez PC; Rodríguez G; González G; Lage A
    MEDICC Rev; 2010; 12(1):17-23. PubMed ID: 20387330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer.
    Neninger E; Verdecia BG; Crombet T; Viada C; Pereda S; Leonard I; Mazorra Z; Fleites G; González M; Wilkinson B; González G; Lage A
    J Immunother; 2009 Jan; 32(1):92-9. PubMed ID: 19307998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients.
    Rodriguez PC; Popa X; Martínez O; Mendoza S; Santiesteban E; Crespo T; Amador RM; Fleytas R; Acosta SC; Otero Y; Romero GN; de la Torre A; Cala M; Arzuaga L; Vello L; Reyes D; Futiel N; Sabates T; Catala M; Flores YI; Garcia B; Viada C; Lorenzo-Luaces P; Marrero MA; Alonso L; Parra J; Aguilera N; Pomares Y; Sierra P; Rodríguez G; Mazorra Z; Lage A; Crombet T; Neninger E
    Clin Cancer Res; 2016 Aug; 22(15):3782-90. PubMed ID: 26927662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine.
    García B; Neninger E; de la Torre A; Leonard I; Martínez R; Viada C; González G; Mazorra Z; Lage A; Crombet T
    Clin Cancer Res; 2008 Feb; 14(3):840-6. PubMed ID: 18245547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer.
    Xing P; Wang H; Yang S; Han X; Sun Y; Shi Y
    BMC Immunol; 2018 Apr; 19(1):14. PubMed ID: 29661145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy.
    Gonzalez G; Crombet T; Torres F; Catala M; Alfonso L; Osorio M; Neninger E; Garcia B; Mulet A; Perez R; Lage R
    Ann Oncol; 2003 Mar; 14(3):461-6. PubMed ID: 12598354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials.
    González G; Crombet T; Neninger E; Viada C; Lage A
    Hum Vaccin; 2007; 3(1):8-13. PubMed ID: 17204867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer.
    Crombet Ramos T; Rodríguez PC; Neninger Vinageras E; Garcia Verdecia B; Lage Davila A
    Expert Rev Vaccines; 2015; 14(10):1303-11. PubMed ID: 26295963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CIMAvax-EGF: Toward long-term survival of advanced NSCLC.
    Saavedra D; Neninger E; Rodriguez C; Viada C; Mazorra Z; Lage A; Crombet T
    Semin Oncol; 2018 Jan; 45(1-2):34-40. PubMed ID: 30318082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines.
    Ruiz R; Hunis B; Raez LE
    Curr Oncol Rep; 2014 Sep; 16(9):400. PubMed ID: 25030654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine.
    Tagliamento M; Rijavec E; Barletta G; Biello F; Rossi G; Grossi F; Genova C
    Expert Opin Biol Ther; 2018 Jul; 18(7):829-835. PubMed ID: 29936901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial.
    González G; Crombet T; Catalá M; Mirabal V; Hernández JC; González Y; Marinello P; Guillén G; Lage A
    Ann Oncol; 1998 Apr; 9(4):431-5. PubMed ID: 9636835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule.
    Popa X; García B; Fuentes KP; Huerta V; Alvarez K; Viada CE; Neninger E; Rodríguez PC; González Z; González A; Crombet T; Mazorra Z
    Oncoimmunology; 2020 May; 9(1):1762465. PubMed ID: 32923124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic vaccination with an EGF-based vaccine in lung cancer: a step in the transition to a chronic disease.
    Rodriguez G; Gonzalez G; Crombet T; Lage A
    Expert Rev Respir Med; 2011 Jun; 5(3):337-42. PubMed ID: 21702656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying predictive biomarkers of CIMAvaxEGF success in non-small cell lung cancer patients.
    Lorenzo-Luaces P; Sanchez L; Saavedra D; Crombet T; Van der Elst W; Alonso A; Molenberghs G; Lage A
    BMC Cancer; 2020 Aug; 20(1):772. PubMed ID: 32807114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor vaccine in non-small-cell lung cancer.
    Gonzalez Marinello GM; Santos ES; Raez LE
    Expert Rev Anticancer Ther; 2012 Apr; 12(4):439-45. PubMed ID: 22500681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma.
    O'Brien ME; Saini A; Smith IE; Webb A; Gregory K; Mendes R; Ryan C; Priest K; Bromelow KV; Palmer RD; Tuckwell N; Kennard DA; Souberbielle BE
    Br J Cancer; 2000 Oct; 83(7):853-7. PubMed ID: 10970684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF-directed Agent for Advanced NSCLC.
    Rosell R; Neninger E; Nicolson M; Huber RM; Thongprasert S; Parikh PM; D'Hondt E
    J Thorac Oncol; 2016 Nov; 11(11):1954-1961. PubMed ID: 27566188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.